

=> b reg

FILE 'REGISTRY' ENTERED AT 14:06:28 ON 15 MAR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 MAR 2006 HIGHEST RN 876856-38-1  
DICTIONARY FILE UPDATES: 14 MAR 2006 HIGHEST RN 876856-38-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d que sta l16

L16 22 SEA FILE=REGISTRY ABB=ON PLU=ON (MEISNDSLDFSSFFPQLSPPADPETPL  
LPSFSAPPKHLSSLRYKTELCSRYAESGFCAYRNRQCFAHGLSELRPPVQHPKYKTELCRS  
FHVLTGCNYGLRCLFIHSPQERREPPVLPDNLSPPPRYGGPYRERCRLWSAPGGCPYGARCH  
FQHPKSARETCRHFAALGDCPYGACCHFSHPPLDRWGSGTKNSSGSLSPSDPDSDPTPVLS  
ESPANNAFSSLLPLALRLQILGDDDLPTASDPLPGDDTDLPLGDEEIAQGLLSVLG) | (M  
DLTAIYESLLSLSPDVPVPSDHGGTESSPGWGSSGPWSLSPSDSSPSGVT SRLPGRSTSLVEG  
RSCGWVPPPPGFAPLAPRLGPELSPSPTSPTATSTTPSRYKTELCRTFSESGRCRYGAKCQFA  
HGLGELRQANRHPKYKTELCHKFYLGRCPCPYGSRCHFIHNPSEDLAAPGHPPVLRQSI SFSGL  
PSGRRTSPPPPGLAGPSLSSSSFSPPSSPPPPGDLPLSPSAFSAAPGTPLARRDPTPVCCPSC  
RRATPISVWGPLGGLVRTPSVQSLGSD) (PDEYASSGSSLGSDSPVFEAGVFAPPQVAAPR  
RLPIFNRI SVSE)/SQSP

=> d que sta l32

L31 77 SEA FILE=REGISTRY ABB=ON PLU=ON (((TUMOUR OR TUMOR)  
(1W)NECRO? (1W)FACTOR# OR TNF) (1W)ALPHA OR TNFA) (L) (RNA  
OR MRNA))/CNS  
L32 77 SEA FILE=REGISTRY ABB=ON PLU=ON AU/SQSN AND L31

=> b hcap

FILE 'HCAPLUS' ENTERED AT 14:06:42 ON 15 MAR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Mar 2006 VOL 144 ISS 12  
FILE LAST UPDATED: 14 Mar 2006 (20060314/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitind hitstr 138 tot

L38 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:673041 HCAPLUS  
DN 143:147736  
TI Methods of using databases to create gene-expression microarrays, equine and canine microarrays created thereby, and uses of the microarrays  
IN Bertone, Alicia; Gu, Weisong  
PA The Ohio State University, USA  
SO PCT Int. Appl., 1475 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2005067649	A2	20050728	2005WO-US00517	20050107
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	WO2005067649	A2	20050728	2005WO-XA00517	20050107
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	2004US-535111P	P	20040108		
	2005WO-US00517	A	20050107		

AB Methods of preparing biol. databases, and databases prepared according to those methods. The methods can be performed entirely using computer resources, relying solely on publicly available biol. sequence information, and can be used to generate species-specific nucleic acid microarrays. The approach involves two major steps: identification of the 3' coding domains (CDSs) and 3' expressed sequence tags (ESTs) in public domain sequence

databases and subsequent annotation of the sequences. For the algorithm using 20,022 equine sequences in GenBank (June, 2003), the 3' equine CDSs are identified by selecting the full and partial CDSs that have a stop codon at the 3' end. This approach ensures that sequences selected are anchored to the 3' end; most contain the 3' untranslated region (UTR), which is more species-specific, compared with the coding region. Use of the UTR sequence in probe design is an asset for improvement of microarray accuracy. An algorithm analyzes the partial equine CDSs and ESTs with those in a human-mouse CDS database (a subset of the GenBank nonredundant database) in order to provide annotation to the selected 3' equine sequences. A total of 3099 equine 3' coding sequences and 3' ESTs are selected for the equine-specific gene expression array, and 68,266 oligonucleotide probes designed according to Affymetrix's chip design guide. Microarray anal. identified genes expressed in equine synoviocytes in the absence and presence of lipopolysaccharide, as well as differentially expressed genes in developmental orthopedic disease (osteocondrosarcoma and cervical vertebral malformation), equine osteoarthritis, equine protozoal myelitis, herpes virus-1 infection, potentially compromising stress, and laminitis in horses. Analogous methods are used to generate a canine-specific microarray to detect gene expression during osteoarthritis in dogs. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IC ICM C12N

CC 3-1 (Biochemical Genetics)

Section cross-reference(s): 13, 14

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(α- TTP (α-tocopherol-transfer protein), gene used

in microarray; methods of using databases to create gene-expression

microarrays, equine and canine microarrays created thereby, and uses of

the microarrays)

IT 134911-17-4 134911-21-0 134911-23-2 134911-26-5 136217-80-6, DNA  
(Canis familiaris clone D41/D44 glycoprotein GP 2 cDNA) 139793-18-3, DNA  
(Canis familiaris clone RDC7 cDNA) 139793-23-0, GenBank M35521  
139793-24-1 139844-55-6, DNA (horse transferrin cDNA plus flanks)  
139846-49-4 139847-57-7 139898-19-4 139898-21-8 140012-92-6,  
GenBank X05297 140012-96-0 140012-97-1, GenBank M33826 140012-98-2  
140012-99-3, DNA (Canis familiaris clone RDC4 cDNA) 140013-00-9  
140013-01-0, DNA (Canis familiaris clone RDC8 cDNA) 140013-04-3, GenBank  
M32283 140013-05-4, GenBank Y00399 140013-06-5, GenBank M35302  
140013-18-9, GenBank M14546 140013-19-0, DNA (Equus caballus zeta globin  
gene) 140061-99-0 140066-19-9, GenBank M14544 140076-21-7  
140076-22-8 140083-38-1 140095-76-7 140098-92-6 140261-32-1, DNA  
(Canis familiaris precursor cDNA) 140261-34-3, GenBank M17177  
140261-35-4, GenBank M17178 140261-41-2, GenBank M29611 140261-47-8,  
GenBank M35520 140261-48-9, GenBank M35522 140261-52-5, GenBank J04067  
140261-53-6 140261-54-7, GenBank J05069 140261-63-8 140261-64-9,  
GenBank M14545 140321-56-8 140330-41-2 140330-43-4 140331-04-0  
140331-05-1 140333-10-4 140335-50-8, DNA (Canis familiaris calcitonin  
cDNA) 140338-42-7 140497-03-6, DNA (Canis familiaris LH precursor  
cDNA) 140497-06-9, GenBank M35301 140497-08-1 140540-10-9, DNA  
(Equus caballus gene CG cDNA) 140729-04-0, GenBank M29957 140729-34-6,  
DNA (Equus caballus alpha 2 globin gene) 141009-94-1 141162-34-7  
141165-97-1, DNA (Canis familiaris gene ICln cDNA) 141372-18-1  
142101-76-6 142318-38-5 142455-67-2 142480-77-1, DNA (Equus caballus  
gene FLAP cDNA) 142830-20-4 142883-14-5 143002-99-7 143525-11-5,  
DNA (Equus caballus gene lipase cDNA) 144507-51-7 144507-52-8  
144893-66-3, DNA (Canis familiaris gene K-ras cDNA) 144915-61-7  
145408-43-1 146169-94-0 146494-33-9, GenBank L01473 147457-85-0  
147904-27-6 148211-93-2 148281-51-0 148427-45-6 148543-29-7  
149346-66-7 149448-13-5 149448-14-6 149766-73-4 149766-75-6  
149766-78-9 149766-79-0 149767-79-3 149974-81-2 150121-66-7  
150201-34-6 150419-58-2 150532-69-7 150532-70-0 151116-49-3, DNA  
(Canis familiaris E-selectin cDNA) 151241-71-3 151246-66-1

151494-43-8 151551-41-6 151579-69-0 151631-74-2 152282-45-6  
152371-39-6 152394-12-2 152394-13-3 153637-50-4 153771-18-7  
153792-44-0 153792-45-1 153794-66-2, GenBank L29489 153794-67-3,  
GenBank L29490 154167-97-2 154448-78-9 154980-06-0 154982-96-4  
155461-23-7 155484-89-2 156709-68-1 157112-26-0 157152-63-1  
157344-13-3 157883-49-3 158024-87-4 158024-88-5 158085-35-9  
158158-33-9 158160-85-1 158449-39-9 158644-08-7 158762-41-5  
158995-05-2 159317-15-4 160043-38-9 160610-51-5 160897-61-0  
160966-61-0 161309-36-0 161781-54-0 162076-76-8  
162114-30-9 162159-77-5 162197-61-7 162487-84-5 164249-75-6  
164687-11-0 164687-63-2, DNA (Canis familiaris gene GMP140 cDNA)  
164687-70-1 164687-72-3 165411-95-0 165474-06-6 165757-59-5  
165906-50-3 165906-81-0 165998-05-0 166229-81-8 166840-99-9  
166841-19-6 167329-00-2 168579-61-1 168854-84-0 169071-41-4  
170176-34-8 170176-79-1 170205-82-0, DNA (Equus caballus gene IL-10  
cDNA) 170206-30-1 170247-47-9 170336-72-8 170404-26-9  
170549-82-3 170829-96-6 170896-08-9, DNA (Canis familiaris gene RDS  
cDNA) 171710-89-7 171840-05-4 171958-03-5 172135-40-9  
172176-79-3 172776-50-0 173295-39-1, DNA (Canis familiaris caveolin-1  
cDNA) 173892-25-6 174386-92-6 174386-93-7 174387-85-0  
174387-87-2 174450-25-0 175033-59-7 175107-82-1 175114-53-1  
175384-44-8, DNA (Equus caballus gene TSH-beta cDNA) 175484-65-8  
175641-31-3 175824-10-9 176454-80-1 176458-04-1 176458-06-3  
176458-59-6, DNA (horse protein Mx $\alpha$  cDNA plus flanks) 176947-53-8  
177307-96-9 177526-87-3, DNA (Canis familiaris SRP14 cDNA) 178085-88-6  
178094-21-8 178147-77-8 178298-26-5, DNA (horse beta-lactoglobulin I  
cDNA) 178298-99-2 178300-32-8 178300-38-4 178356-39-3, DNA (horse  
beta-lactoglobulin II cDNA) 178836-58-3 179708-49-7, DNA (Equus  
caballus clone I7 cDNA) 179789-79-8 179789-80-1 179956-58-2  
180563-10-4 181109-73-9 181727-57-1 182456-78-6 182521-47-7  
183575-13-5 184513-16-4 184659-86-7 184859-12-9 185082-18-2  
185082-19-3 185082-20-6 185236-09-3 185239-95-6 185979-49-1  
187132-36-1 187132-37-2 188222-48-2, DNA (Canis familiaris biglycan  
cDNA) 188222-49-3, DNA (Canis familiaris decorin cDNA) 188333-61-1  
190046-24-3 190211-31-5  
RL: BUU (Biological use, unclassified); DGN (Diagnostic use); PRP  
(Properties); BIOL (Biological study); USES (Uses)  
(nucleotide sequence; methods of using databases to create  
gene-expression microarrays, equine and canine microarrays created  
thereby, and uses of the microarrays)  
IT 161309-36-0  
RL: BUU (Biological use, unclassified); DGN (Diagnostic use); PRP  
(Properties); BIOL (Biological study); USES (Uses)  
(nucleotide sequence; methods of using databases to create  
gene-expression microarrays, equine and canine microarrays created  
thereby, and uses of the microarrays)  
RN 161309-36-0 HCAPLUS  
CN DNA (Canis familiaris clone pDog-TNF- $\alpha$  tumor necrosis factor  $\alpha$   
cDNA plus flanks) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN  
AN 2001:137044 HCAPLUS  
DN 134:189743  
TI Binding of tristetraprolin (TTP)-related CCCH zinc  
finger proteins to AU-rich elements of mRNA and uses thereof in treatment  
of granulocytopenia by regulating GM-CSF mRNA stability  
IN Blackshear, Perry J.; Lai, Wi S.; Carballo-Jane, Ester  
PA United States Dept. of Health and Human  
Services, USA  
SO PCT Int. Appl., 133 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2001012213	A2	20010222	2000WO-US22199	20000814 <--
	WO2001012213	A3	20010607		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU2000066388	A5	20010313	2000AU-0066388	20000814 <--
PRAI	1999US-148810P	P	19990813	<--	
	2000WO-US22199	W	20000814	<--	
AB	The invention provides methods based upon the discovery that <b>tristetraprolin (TTP)</b> and <b>TTP-related proteins</b> stimulate the destruction of certain mRNAs by binding to an AU-rich element (ARE) within the 3' untranslated region of such mRNAs, and that the zinc finger domain of <b>TTP</b> and <b>TTP-related proteins</b> is sufficient to mediate this destruction. The present invention provides methods of regulating the destruction of mRNA mols. containing an AU-rich element (ARE) by <b>tristetraprolin (TTP)</b> -related CCCH zinc finger proteins, for example, methods of stimulating the degradation of an mRNA mol. encoding TNF- $\alpha$ , and methods of inhibiting the degradation of an mRNA mol. encoding GM-CSF. Also provided are methods for identifying compds. that regulate the destruction of mRNA mols. containing AREs. The invention also features a method of treating granulocytopenia by administering <b>TTP</b> -related zinc finger proteins for inhibiting the degradation of GM-CSF mRNA.				
IC	ICM A61K-0038/17				
CC	ICS A61K-0048/00; C12N-0015/12; C07K-0014/47; A61P-0007/00				
	6-3 (General Biochemistry)				
	Section cross-reference(s): 1, 3, 13				
ST	CCCH zinc finger protein mRNA interaction; <b>tristetraprolin</b> mRNA AU element interaction; tumor necrosis factor mRNA destabilization <b>tristetraprolin</b> related protein; Colonystimulating factor 2 tandem zinc finger protein granulocytopenia therapy; mRNA stability regulation <b>tristetraprolin</b> related CCCH zinc finger protein				
IT	Genetic element				
	RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process) (ARE (AU-rich element), class II; binding of <b>tristetraprolin (TTP)</b> -related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)				
IT	Proteins, specific or class				
	RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (C124R, mutant <b>TTP</b> ; binding of <b>tristetraprolin (TTP)</b> -related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)				
IT	Proteins, specific or class				
	RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (C147R, mutant <b>TTP</b> ; binding of <b>tristetraprolin (TTP)</b> -related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)				
IT	Proteins, specific or class				
	RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (CCCH zinc finger-containing; binding of <b>tristetraprolin (TTP)</b> -related CCCH zinc finger proteins to AU-rich elements of				

- mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Proteins, specific or class  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ERF1; binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Proteins, specific or class  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ERF2; binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(TNF $\alpha$  mRNA destabilization; binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Gene, animal  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**TTP**; binding of **tristetraprolin (TTP)**)-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Proteins, specific or class  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(XC3H-4, TZF-containing protein; binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Drug screening  
Molecular cloning  
(binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Drugs  
(comprising **TTP** or **TTP**-related proteins or agents regulating **TTP** activity; treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Cytoplasm  
(cytosol, mRNA in; binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Genetic vectors  
(for expressing **TTP** or **TTP**-related protein; binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Molecular association  
(mRNA binding; binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Enzymes, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(mRNA degradative; binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Cell  
(mRNA in; binding of **tristetraprolin (TTP)**-related

- CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Interleukin 3  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(mRNA stability; binding of **tristetraprolin (TTP)**  
) -related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Mutation  
(of **TTP** or **TTP**-related proteins, for treating granulocytopenia; treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Agranulocytosis  
(relative or absolute, treatment of; binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT mRNA  
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)  
(stability, degradation; binding of **tristetraprolin (TTP)**  
) -related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Repeat motifs (protein)  
(tandem zinc finger (TZF); binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Proteins, specific or class  
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(**tris-tetraprolins**, interaction with mRNA; binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT Protein motifs  
(zinc finger; binding of **tristetraprolin (TTP)**  
) -related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT 83869-56-1, GM-CSF  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(mRNA stability regulated by **TTP**; binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT 326947-75-5 326947-76-6 326947-77-7  
326947-78-8 326947-85-7 326947-86-8  
RL: PRP (Properties)  
(unclaimed nucleotide sequence; binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)
- IT 139691-22-8, **Tris-tetraprolin** (human gene  
ZFP36 reduced) 161706-34-9, Protein ERF-2 (human gene ERF-2)  
229160-23-0 326947-63-1 326947-64-2 326947-65-3  
326947-66-4 327026-01-7 327026-04-0 327026-07-3 327026-08-4  
327026-13-1 327026-18-6 327026-25-5 327026-27-7 327026-57-3  
327026-66-4 327026-77-7 327026-80-2  
RL: PRP (Properties)  
(unclaimed protein sequence; binding of **tristetraprolin (TTP)**-related CCCH zinc finger proteins to AU-rich elements of mRNA and uses thereof in treatment of granulocytopenia by regulating

GM-CSF mRNA stability)

IT 157079-69-1 165588-58-9 326947-79-9  
 326947-80-2 326947-81-3 326947-82-4  
 326947-83-5 326947-84-6  
 RL: PRP (Properties)  
 (unclaimed sequence; binding of tristetraprolin (TTP  
 )-related CCCH zinc finger proteins to AU-rich elements of mRNA and  
 uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA  
 stability)

IT 326947-75-5 326947-76-6 326947-77-7  
 326947-78-8 326947-85-7 326947-86-8  
 RL: PRP (Properties)  
 (unclaimed nucleotide sequence; binding of tristetraprolin (TTP)-related CCCH zinc finger proteins to AU-rich elements of  
 mRNA and uses thereof in treatment of granulocytopenia by regulating  
 GM-CSF mRNA stability)

RN 326947-75-5 HCAPLUS  
 CN DNA, d(G-T-C-G-A-C-A-C-T-C-A-G-A-G-A-G-A-A-A-G-G-C-T-A-A-G-G) (9CI) (CA  
 INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 326947-76-6 HCAPLUS  
 CN DNA, d(C-A-T-T-C-A-A-A-G-G-G-G-A-T-A-T-C-A-G-T-C-A-G) (9CI) (CA INDEX  
 NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 326947-77-7 HCAPLUS  
 CN DNA, d(G-T-G-G-C-T-T-C-T-A-G-A-T-G-C-A-T-G-G-G-T-G-G-C-A-T-C) (9CI) (CA  
 INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 326947-78-8 HCAPLUS  
 CN DNA, d(G-A-A-G-G-A-C-A-C-C-T-C-T-A-G-A-G-A-C-A-A-A-A-T-G-A-T-G-C) (9CI)  
 (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 326947-85-7 HCAPLUS  
 CN 48: PN: WO0112213 SEQID: 24 unclaimed DNA (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 326947-86-8 HCAPLUS  
 CN 49: PN: WO0112213 SEQID: 25 unclaimed RNA (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 139691-22-8, Tris-tetraprolin (human gene  
 ZFP36 reduced) 229160-23-0  
 RL: PRP (Properties)  
 (unclaimed protein sequence; binding of tristetraprolin (TTP)-related CCCH zinc finger proteins to AU-rich elements of  
 mRNA and uses thereof in treatment of granulocytopenia by regulating  
 GM-CSF mRNA stability)

RN 139691-22-8 HCAPLUS  
 CN Tris-tetraprolin (human gene ZFP36 reduced) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 229160-23-0 HCAPLUS  
 CN CCCH zinc finger protein C3H-4 (Xenopus laevis gene C3H-4) (9CI) (CA  
 INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 157079-69-1 165588-58-9 326947-79-9  
 326947-80-2 326947-81-3 326947-82-4  
 326947-83-5 326947-84-6  
 RL: PRP (Properties)  
 (unclaimed sequence; binding of tristetraprolin (TTP  
 )-related CCCH zinc finger proteins to AU-rich elements of mRNA and




uses thereof in treatment of granulocytopenia by regulating GM-CSF mRNA stability)

RN 157079-69-1 HCAPLUS

CN L-Cysteine, L-methionyl-L-arginyl-L-threonyl-L- $\alpha$ -glutamyl-L-asparaginylglycyl-L-lysyl-L-seryl-L-lysylglycyl-L-phenylalanylglycyl-L-phenylalanyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

SH

PAGE 2-A



RN 165588-58-9 HCAPLUS

CN RNA, (U-U-A-U-U-U-A-U-U) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 326947-79-9 HCAPLUS  
 CN DNA, d(C-T-T-T-C-C-G-A-A-T-T-C-A-C-T-G-G-A-G-C-C-T-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 326947-80-2 HCAPLUS  
 CN DNA, d(T-A-G-A-T-C-T-A-G-A-A-G-C-G-A-T-C-T-T-T-A-T-T-T-C-T-C-T-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 326947-81-3 HCAPLUS  
 CN DNA, d(G-A-T-A-A-G-A-T-C-T-C-A-G-G-C-C-T-T-C-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 326947-82-4 HCAPLUS  
 CN DNA, d(G-C-C-T-T-C-T-A-G-A-T-A-A-A-T-A-C-A-T-T-C-A-T-A-A-G-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 326947-83-5 HCAPLUS  
 CN DNA, d(C-T-G-A-T-C-T-A-G-A-A-G-T-G-C-A-A-A-T-A-T-A-A-A-T-A-G-A-G-G) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 326947-84-6 HCAPLUS  
 CN DNA, d(G-A-C-T-G-G-A-T-C-C-T-C-T-A-T-T-T-A-T-A-T-T-T-G-C-A-C) (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

=> d his

(FILE 'HOME' ENTERED AT 13:27:28 ON 15 MAR 2006)

FILE 'HCAPLUS' ENTERED AT 13:27:38 ON 15 MAR 2006

L1 2 (US2002-049486 OR WO2000-US22199 OR US1999-148810#)/AP, PRN  
 SEL AN 2  
 L2 1 E1-2 AND L1  
 E BLACKSHEAR P/AU  
 L3 195 E3-4, E10-13  
 E LAI W/AU  
 L4 90 E3, E19  
 E LAI WI/AU  
 L5 39 E4  
 E CARBALLO E/AU  
 L6 60 E3, E5-6  
 E CABALLO JANE E/AU  
 E JANE E/AU  
 L7 15 E3-5  
 L8 4222 (HHS OR HEALTH (L) HUMAN (L) SERV?)/CS, PA

FILE 'REGISTRY' ENTERED AT 13:32:46 ON 15 MAR 2006

FILE 'HCAPLUS' ENTERED AT 13:32:50 ON 15 MAR 2006

L9 TRA L2 1- RN : 34 TERMS

FILE 'REGISTRY' ENTERED AT 13:32:50 ON 15 MAR 2006

L10 34 SEA L9  
 L11 20 L10 AND PROTEIN/FS  
 SEL RN 17 20  
 L12 2 E1-2 AND L11  
 L13 QUE MEISNDSLDFSSFFPQLSPPADPETPLLPFSAPPKHLSSLRYKTELCSTRYAESGF  
 L14 QUE MDLTAIYESLLSLSPDVPVPSDHGGTESSPGWGSSGPWSLSPSDSSPSGVTSRLPGRST  
 L15 QUE PDEYASSGSSLGSDSPVFEAGVFAPPQPVAAPRRLPINFNRISVSE/SQSP  
 L16 22 L13|L14&L15/SQSP

L17 FILE 'HCAPLUS' ENTERED AT 13:47:53 ON 15 MAR 2006  
29 L16  
L18 2835 TTP OR TRISTETRAPROLIN#  
L19 2855 L17-18

L20 FILE 'REGISTRY' ENTERED AT 13:48:34 ON 15 MAR 2006  
14 L10 NOT L11

FILE 'STNGUIDE' ENTERED AT 13:50:56 ON 15 MAR 2006

L21 FILE 'REGISTRY' ENTERED AT 13:51:44 ON 15 MAR 2006  
18 L11 NOT L12

L22 FILE 'HCAPLUS' ENTERED AT 13:53:35 ON 15 MAR 2006  
41 TRIS (1W)TETRAPROLIN#

L23 FILE 'REGISTRY' ENTERED AT 13:55:40 ON 15 MAR 2006  
13 L10 AND SQL/FA AND NUCLEIC/FS

L24 FILE 'HCAPLUS' ENTERED AT 13:56:38 ON 15 MAR 2006  
1 L23 AND L2

L25 FILE 'REGISTRY' ENTERED AT 13:57:15 ON 15 MAR 2006  
1 157079-69-1

L26 FILE 'HCAPLUS' ENTERED AT 13:57:46 ON 15 MAR 2006  
5 L23,L25  
L27 1 L26 AND L19,L22

L28 FILE 'MEDLINE' ENTERED AT 13:58:43 ON 15 MAR 2006  
0 L27

L29 FILE 'EMBASE' ENTERED AT 13:59:06 ON 15 MAR 2006  
0 L27

L30 FILE 'BIOSIS' ENTERED AT 13:59:13 ON 15 MAR 2006  
0 L27

L31 FILE 'REGISTRY' ENTERED AT 13:59:34 ON 15 MAR 2006  
77 (((TUMOUR OR TUMOR) (1W)NECRO? (1W)FACTOR# OR TNF) (1W)ALPHA OR  
L32 77 AU/SQSN AND L31

L33 FILE 'HCAPLUS' ENTERED AT 14:02:34 ON 15 MAR 2006  
31 L32  
L34 1 L33 AND L19,L22  
L35 2 L27,L34  
L36 1 L35 AND L1-8  
L37 1 L35 NOT L36  
L38 2 L35-37

L39 FILE 'MEDLINE' ENTERED AT 14:04:44 ON 15 MAR 2006  
0 L34

L40 FILE 'EMBASE' ENTERED AT 14:05:02 ON 15 MAR 2006  
0 L34

L41 FILE 'BIOSIS' ENTERED AT 14:05:12 ON 15 MAR 2006  
0 L34

FILE 'REGISTRY' ENTERED AT 14:05:21 ON 15 MAR 2006  
SAV TEM L16 SIS586F0/A  
SAV TEM L32 SIS586F1/A

=&gt;